Catalyst Event
Teva Pharmaceutical Industries Ltd (TEVA) · Earnings Release
From KEDI Global Longevity Bio Index (KGLB)
4/29/2026, 12:00:00 AM
Teva is scheduled to release its financial results for the first quarter of 2026 before the market opens on April 29, 2026, followed by a conference call with management; a 5% price impact is estimated for this earnings release, scheduled.
Korean Translation
Teva, 2026년 4월 29일 1분기 재무 실적을 장 시작 전에 발표하고 경영진과의 컨퍼런스 콜을 진행할 예정이며, 실적 발표에 따른 5% 수준의 주가 변동이 예상됨.
Related Recent Events
Biogen Inc (BIIB) · Other
U.S. FDA decision (PDUFA date) for LEQEMBI IQLIK (lecanemab) subcutaneous autoinjector for treatment initiation in Alzheimer's disease on 2026-05-24; high importance is estimated as FDA approval for a major drug formulation typically results in ≥10% price impact, scheduled.
5/24/2026, 12:00:00 AM
Exelixis Inc (EXEL) · Earnings Release
Exelixis is expected to report its Q1 2026 earnings on or around May 12, 2026, and analysts forecast EPS of approximately $0.73-$0.76; high importance reflects potential volatility from earnings surprises, forecasted and scheduled.
5/12/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release scheduled. Analysts forecast EPS around $7.25-$7.50 estimated. High importance estimated due to the significant weight of earnings reports on stock volatility.
4/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Bristol Myers Squibb Q1 2026 results conference call is scheduled for 2026-04-30; as the next earnings catalyst following the strong Q4 2025 outlook, a multi-percent share move is reasonably expected based on typical earnings volatility scheduled.
4/30/2026, 12:00:00 AM
AbbVie Inc (ABBV) · Earnings Release
First quarter 2026 earnings release; importance is estimated as Medium because quarterly earnings reports often result in price movements exceeding 5%, scheduled.
4/24/2026, 12:00:00 AM
Thermo Fisher Scientific Inc (TMO) · Earnings Release
Q1 2026 earnings release is scheduled.
4/22/2026, 12:00:00 AM